Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CD4 | P01730 | 2/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150535 | 0.93 | NR3C1 (0.47) | MEN1KMT2APKMNR3C1KDM4E | |
| SCHEMBL2346588 | 0.92 | CD4 (0.51) | PKMNR3C1TSHRALDH1A1CD4 | |
| SCHEMBL2355541 | 0.92 | MEN1 (0.49) | MEN1KMT2APKMNR3C1TSHR | |
| SCHEMBL14150516 | 0.90 | NR3C1 (0.49) | MEN1KMT2ANR3C1KDM4EALDH1A1 | |
| SCHEMBL2348930 | 0.90 | ALDH1A1 (0.42) | KMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL6909830 | 0.90 | AKR1C3 (0.41) | MEN1KMT2APKMNR3C1TSHR | |
| SCHEMBL2355058 | 0.90 | NR3C1 (0.48) | MEN1KMT2ANR3C1ALDH1A1CD4 | |
| SCHEMBL2357824 | 0.90 | PKM (0.44) | MEN1KMT2APKMNR3C1TSHR | |
| SCHEMBL2356653 | 0.90 | LMNA (0.55) | MEN1KMT2APKMNR3C1TSHR | |
| SCHEMBL2354783 | 0.87 | NR3C1 (0.51) | PKMNR3C1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | claimed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| EP-2536721-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | MEN1 4805/4885KMT2A 3349/4885PKM 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.